NeuroOne files prospectus to sell up to $13.4M in common stock via ATM program with JonesTrading

NEUROONE MEDICAL TECHNOLOGIES Corp

Updated prospectus supplement filed June 12, 2026 for at-the-market offering of up to $13.4M of common stock.
Shares to be sold through JonesTrading Institutional Services LLC under existing Capital on Demand Sales Agreement.
Program originally established December 2022; latest supplement updates the offering amount and conditions.
Legal opinion from Honigman LLP regarding the Shares is included as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.